[{"address1": "400 Alexander Park Drive", "address2": "4th Floor", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "646 768 9780", "website": "https://www.urogen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft f\u00fcr klinische Spezialpr\u00e4parate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.", "fullTimeEmployees": 217, "companyOfficers": [{"maxAge": 1, "name": "Ms. Elizabeth A. Barrett", "age": 61, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1338806, "exercisedValue": 0, "unexercisedValue": 364000}, {"maxAge": 1, "name": "Mr. Jason Drew Smith J.D.", "age": 51, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 864188, "exercisedValue": 0, "unexercisedValue": 72800}, {"maxAge": 1, "name": "Dr. Mark P. Schoenberg M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 639832, "exercisedValue": 0, "unexercisedValue": 29273}, {"maxAge": 1, "name": "Mr. Christopher  Degnan CPA", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent I. Perrone", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryon  Wornson", "title": "Executive Vice President of Talent, Advocacy & Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marina  Konorty Ph.D.", "title": "Executive Vice President of Research & Development and Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Ottinger R.ph.", "title": "Executive Vice President of Regulatory Affairs & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D.", "age": 58, "title": "Chief Business Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J. Louie M.D., M.P.H., M.Sc.", "title": "Senior Vice President of Medical Affairs & Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.47, "open": 11.43, "dayLow": 11.1, "dayHigh": 11.5, "regularMarketPreviousClose": 11.47, "regularMarketOpen": 11.43, "regularMarketDayLow": 11.1, "regularMarketDayHigh": 11.5, "beta": 1.126, "forwardPE": -4.260047, "volume": 314971, "regularMarketVolume": 314971, "averageVolume": 558859, "averageVolume10days": 349970, "averageDailyVolume10Day": 349970, "bid": 11.25, "ask": 11.42, "bidSize": 100, "askSize": 100, "marketCap": 478963200, "fiftyTwoWeekLow": 10.6, "fiftyTwoWeekHigh": 20.7, "priceToSalesTrailing12Months": 5.3597484, "fiftyDayAverage": 12.191, "twoHundredDayAverage": 14.096425, "currency": "USD", "enterpriseValue": 352134336, "profitMargins": -1.29112, "floatShares": 24530097, "sharesOutstanding": 42199400, "sharesShort": 5773140, "sharesShortPriorMonth": 6599031, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.1368, "heldPercentInsiders": 0.09178001, "heldPercentInstitutions": 0.92232, "shortRatio": 12.42, "shortPercentOfFloat": 0.14, "impliedSharesOutstanding": 42199400, "bookValue": 0.605, "priceToBook": 18.76033, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -115378000, "trailingEps": -3.02, "forwardEps": -2.66, "enterpriseToRevenue": 3.94, "enterpriseToEbitda": -4.228, "52WeekChange": -0.24383742, "SandP52WeekChange": 0.2764505, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "URGN", "underlyingSymbol": "URGN", "shortName": "UroGen Pharma Ltd.", "longName": "UroGen Pharma Ltd.", "firstTradeDateEpochUtc": 1493904600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5e073096-dd64-3395-84b4-3b44201f1a30", "messageBoardId": "finmb_240702165", "gmtOffSetMilliseconds": -18000000, "currentPrice": 11.35, "targetHighPrice": 64.0, "targetLowPrice": 22.0, "targetMeanPrice": 39.92857, "targetMedianPrice": 40.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 249575008, "totalCashPerShare": 5.914, "ebitda": -83282000, "totalDebt": 122746000, "quickRatio": 8.307, "currentRatio": 9.0, "totalRevenue": 89363000, "debtToEquity": 481.074, "revenuePerShare": 2.389, "returnOnAssets": -0.21120001, "freeCashflow": -49254500, "operatingCashflow": -96143000, "revenueGrowth": 0.209, "grossMargins": 0.90269, "ebitdaMargins": -0.93195, "operatingMargins": -0.69612, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]